Page 1

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549 FORM 20 - F ( Mark One ) REGISTRATION STATEMENT PURSUANT TO SECTION 12 ( b ) OR ( g ) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2020 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report : Not applicable For the transition period from to Commission file number 001-36622 PROQR THERAPEUTICS N.V. ( Exact name of Registrant as specified in its charter ) The Netherlands ( Jurisdiction of incorporation or organization ) Zernikedreef 9 2333 CK Leiden The Netherlands ( Address of principal executive offices ) Smital Shah , Chief Business and Financial Officer Tel : +31 88 166 7000 sshah@proqr.com , Zernikedreef 9 , 2333 CK Leiden , The Netherlands ( Name , Telephone , E - mail and / or Facsimile number and Address of Company Contact Person ) Securities registered or to be registered pursuant to Section 12 ( b ) of the Act : Title of each class Ordinary Shares , nominal value € 0.04 per share | Trading Symbol ( s ) PRQR Name of each exchange on which registered NASDAQ Stock Market Securities registered or to be registered pursuant to Section 12 ( g ) of the Act : None ( Title of Class ) Securities for which there is a reporting obligation pursuant to Section 15 ( d ) of the Act : None ( Title of Class )